In this final podcast of three, Anjan Selz, cofounder and CEO of Finox Biotech, denounces the destructive nature of focusing only on price in the biosimilar space and states that the ability to differentiate and improve a product offering should be the driver for development. Selz notes that differentiation can come in many forms and include new formulations, the delivery device or even packaging. In the case of a "lifestyle" drug like Afolia, the emphasis is offering improved consumer experience. Selz concludes by offering excellent insight into project management and some of the secrets behind moving so quickly through development. Posted Jan. 2012.

Podcast 1 on biosimilar candidate choice and outsourcing

Podcast 2 on meeting regulatory expectations